logo
Science Portal
Copyright © Médecins Sans Frontières
v2.1.5145.produseast1
About MSF Science Portal
About
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use
Copyright © Médecins Sans Frontières
v2.1.5145.produseast1
Showing 1 - 5 of 5 Items
Showing 1 - 5 of 5 Items
Sort By: Relevance
  • Newest to oldest
  • Oldest to newest
  • Relevance
Journal Article
|
Research

Low-dose yellow fever vaccine in adults in Africa

Kimathi D, Juan-Giner A, Bob NS, Orindi B, Namulwana ML,  et al.
2025-02-20 • New England Journal of Medicine
2025-02-20 • New England Journal of Medicine

BACKGROUND

Yellow fever vaccine is highly effective with a single dose, but vaccine supply is limited. The minimum dose requirements for seroconversion remain u...

Journal Article
|
Research

Immunogenicity and safety of fractional doses of 17D-213 yellow fever vaccine in children (YEFE): a randomised, double-blind, non-inferiority substudy of a phase 4 trial

Juan-Giner A, Namulwana ML, Kimathi D, Grantz KH, Fall G,  et al.
2023-04-28 • Lancet Infectious Diseases
2023-04-28 • Lancet Infectious Diseases
BACKGROUND
Current supply shortages constrain yellow fever vaccination activities, particularly outbreak response. Although fractional doses of all WHO-prequalified yellow fever vacc...
Journal Article
|
Research

Randomized, double-blinded, controlled non-inferiority trials evaluating the immunogenicity and safety of fractional doses of Yellow Fever vaccines in Kenya and Uganda

Kimathi D, Aitana J, Bejon P, Grais RF, Warimwe GM,  et al.
2019-11-20 • BMJ Global Health
2019-11-20 • BMJ Global Health
Introduction: Yellow fever is endemic in specific regions of sub-Saharan Africa and the Americas, with recent epidemics occurring on both continents. The yellow fever vaccine is effectiv...
Journal Article
|
Research

Immunogenicity and safety of fractional doses of yellow fever vaccines: a randomised, double-blind, non-inferiority trial

Juan-Giner A, Kimathi D, Grantz KH, Hamaluba M, Kazooba P,  et al.
2021-01-09 • Lancet
2021-01-09 • Lancet
BACKGROUND
Stocks of yellow fever vaccine are insufficient to cover exceptional demands for outbreak response. Fractional dosing has shown efficacy, but evidence is limited to the 17...
Journal Article
|
Research

Single low-dose primaquine for blocking transmission of Plasmodium falciparum malaria - a proposed model-derived age-based regimen for sub-Saharan Africa

Taylor WRJ, Naw HK, Maitland K, Williams TN, Kapulu M,  et al.
2018-01-18 • BMC Medicine
2018-01-18 • BMC Medicine
In 2012, the World Health Organization recommended blocking the transmission of Plasmodium falciparum with single low-dose primaquine (SLDPQ, target dose 0.25 mg base/kg body weight), wi...